Alpha-1 antitrypsin gene therapy

Drug Profile

Alpha-1 antitrypsin gene therapy

Alternative Names: Alpha-antitrypsin gene therapy

Latest Information Update: 14 May 2001

Price : $50

At a glance

  • Originator Vanderbilt University
  • Developer Valentis; Vanderbilt University
  • Class Gene therapies
  • Mechanism of Action Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cystic fibrosis; Emphysema; Respiratory syncytial virus infections

Most Recent Events

  • 14 May 2001 Discontinued-Unspecified Phase in Cystic fibrosis in USA (Inhalation)
  • 14 May 2001 Discontinued-I for Emphysema in USA (Inhalation)
  • 14 May 2001 Discontinued-Preclinical for Respiratory syncytial virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top